Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06673095 · ClinicalTrials.gov registry record · NA

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

A NA study of Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8, sponsored by OHSU Knight Cancer Institute.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
1
Study location

NCT06673095 is a NA study of Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 1,000 participants, above the 504-participant average among 4 other Clinical Stage IA Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (98% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06673095, a NA study of Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
1
Study location

Study Summary

This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tissue surrounding the melanoma) when removing melanoma. Narrow margin excision removes a smaller amount of healthy tissue when surgically removing the melanoma. Narrow margin excision may be effective in removing the melanoma while also reducing surgical complications and improving quality of life for adults with invasive cutaneous melanoma.

Conditions Studied

Clinical Stage IA Cutaneous Melanoma AJCC v8 Clinical Stage IB Cutaneous Melanoma AJCC v8

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Survey Administration
  • PROCEDURE Excision

Study Locations (1)

Oregon

  • OHSU Knight Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-12-11
Est. Completion 2027-12-31
Phase NA

Sponsor

OHSU Knight Cancer Institute

211 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06673095

The ClinicalTrials.gov registry entry for NCT06673095 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 504-participant average among 4 other Clinical Stage IA Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (98% higher). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Clinical Stage IA Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.

NCT06673095 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT06673095 about?

NCT06673095 is a clinical study titled "Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial". This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tissue surrounding the melanoma) when removing melanoma. Narrow ...

What is the current status of trial NCT06673095?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-12-11. Estimated completion is 2027-12-31.

What conditions does trial NCT06673095 study?

This clinical trial studies the following conditions: Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8.

What interventions are being tested in trial NCT06673095?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Excision (PROCEDURE).

Who is sponsoring clinical trial NCT06673095?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06673095 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clinical Stage IA Cutaneous Melanoma AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clinical Stage IA Cutaneous Melanoma AJCC v8

All registered trials for this condition

Clinical Stage IB Cutaneous Melanoma AJCC v8

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.